Lux Biosciences, Inc.

While it is human nature to expect a CEO of a company that has been successful to go on to repeat their triumphs, success may be down to luck or turn out to be elusive in more challenging assignments.

It has not been a good week for Canadian biotech. The sell-off of the crown jewels at QLT ( scripintelligence.com, 25 September 2012 ), the return of rights to Cardiome ( scripintelligence.com, 27 Sep

Isotechnika's share price rose by 12.5% to Can$0.135 after the Canadian firm announced that it had licensed out its lead drug for a secondary indication. Vifor Pharma, the speciality pharma business o

The more things change, the more they stay the same. The satirical 19th-century French critic Jean-Baptiste Alphonse Karr wasn't channeling ophthalmology when he authored that truism in 1849. But the